drugset
drugset / Trial / NCT03202719

Duration of IPV Priming and Antibody Decay

NCT03202719 ↗

Phase 4 Completed 1645 enrolled Centers for Disease Control and Prevention International Centre for Diarrhoeal Disease Research, Bangladesh · collab
RandomizedParallel-groupOpen-labelPrevention

Summary

This is an open-label randomized phase IV clinical trial assessing immunogenicity of poliovirus vaccines.Participants will be enrolled at 6 weeks of age and followed to 18 months of age. The study will recruit 1645 participants in five arms.

Timeline

Start
2017-11-05
Primary completion
2019-10-01
Completion
2019-10-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Inactivated Polio Vaccine Vaccine — —
Comparator Bivalent oral poliovirus vaccine Vaccine — Oral

Indications

poliomyelitis